Trial
NCT02867280
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sun Yat-sen University
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
Sorafenib
Why stopped
Midterm analysis showed negative results.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-02-11